You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,724,394

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,724,394

Title:	Pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as active ingredient
Abstract:	The present invention relates to a pharmaceutical composition for preventing or treating osteoporosis which comprises neuropeptide Y as an active ingredient. The neuropeptide Y according to the present invention reduces the expression of a cell adhesion factor in osteoblasts in which a Y1 receptor is present, and consequently an effect of releasing a haematopoietic stem cell from bone marrow into the blood is excellent. When a haematopoietic stem cell is released into the blood, the number of osteoclasts which induce an osteoporotic lesion by differentiation from the haematopoietic stem cell decreases, and thus progression of a bone erosion caused by osteoclasts can be prevented. Accordingly, the neuropeptide Y which is an active ingredient of the composition of the present invention is useful as a therapeutic agent for osteoporosis.
Inventor(s):	Bae; Jae Sung (Daegu, KR), Jin; Hee Kyung (Daegu, KR), Park; Min Hee (Gyeongsangbuk-do, KR), Lee; Jong Kil (Daegu, KR)
Assignee:	KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY--ACADEMIC COOPERATION FOUNDATION (Daegu, KR)
Application Number:	14/773,375
Patent Claims:	1. A method of treating osteoporosis which comprises administering to a patient in need thereof a pharmaceutical composition comprising neuropeptide Y as an active ingredient. 2. The method according to claim 1, wherein the neuropeptide Y reduces the expression of cell adhesion factors in osteoblasts by acting on the neuropeptide Y receptor Y1 present in the cells. 3. The method according to claim 1, wherein the neuropeptide Y increases the release of bone marrow haematopoietic stem cells from the bone marrow into blood. 4. The method of claim 1, wherein the amount of neuropeptide Y administered is in a range of 0.01 to 1 mg/kg. 5. The method of claim 4, wherein the amount of neuropeptide Y administered is in a range of 0.05 to 0.1 mg/kg. 6. The method of claim 1, wherein the pharmaceutical composition further includes at least one pharmaceutically acceptable carrier. 7. The method of claim 6, wherein the pharmaceutically acceptable carrier is selected from one or more in the group consisting of saline, sterile water, a Ringer's solution, buffered saline, a dextrose solution, a maltodextrin solution, glycerol, and ethanol. 8. The method of claim 1, wherein the pharmaceutical composition further includes one or more auxiliary additives selected from the group consisting of an antioxidant, a buffer, and a bacteriostatic agent. 9. The method of claim 1, wherein the pharmaceutical composition is administered parenterally. 10. The method of claim 1, wherein the pharmaceutical composition is administered orally. 11. The method of claim 1, wherein the neuropeptide Y is administered once per day. 12. The method of claim 1, wherein the neuropeptide Y is administered in divided doses per day.

Details for Patent 9,724,394

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2033-01-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.